Inovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.10.

INO has been the topic of a number of analyst reports. ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 12th. Maxim Group set a $12.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, January 2nd. BidaskClub raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th.

How to Become a New Pot Stock Millionaire

Inovio Pharmaceuticals (NASDAQ INO) opened at $5.15 on Friday. The firm has a market capitalization of $404.11, a price-to-earnings ratio of -4.77 and a beta of 2.55. Inovio Pharmaceuticals has a 12 month low of $3.76 and a 12 month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.06. The company had revenue of $8.80 million for the quarter, compared to the consensus estimate of $9.13 million. Inovio Pharmaceuticals had a negative return on equity of 67.58% and a negative net margin of 208.92%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) EPS. equities research analysts anticipate that Inovio Pharmaceuticals will post -1.37 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its stake in Inovio Pharmaceuticals by 1.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,670 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 897 shares during the period. Voya Investment Management LLC raised its stake in Inovio Pharmaceuticals by 13.8% during the 2nd quarter. Voya Investment Management LLC now owns 31,407 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 3,804 shares during the period. American International Group Inc. raised its stake in Inovio Pharmaceuticals by 29.1% during the 3rd quarter. American International Group Inc. now owns 53,963 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 12,169 shares during the period. Keybank National Association OH raised its stake in Inovio Pharmaceuticals by 41.6% during the 3rd quarter. Keybank National Association OH now owns 42,820 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 12,578 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Inovio Pharmaceuticals by 16.1% during the 3rd quarter. Wells Fargo & Company MN now owns 103,680 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 14,342 shares during the period. 31.81% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of “Buy” by Brokerages” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/inovio-pharmaceuticals-inc-ino-given-consensus-recommendation-of-buy-by-brokerages.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply